Cipla files ANDA for generic version of GSK’s Advair Diskus® Kumar Jeetendra | May 18, 2020 Mumbai, India; May 18, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced its submission of an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the United States Food and Drug Administration (USFDA). The Company had …
Cipla receives final approval for generic version of Migranal® Kumar Jeetendra | May 21, 2020 Mumbai, India; May 21, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (“ANDA”) for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the United States Food and Drug Administration (U.S. FDA) with a Competitive Generic Therapy (“CGT”) …
Cipla expands partnership with Roche Pharma India to further improve access to key oncology medicines Kumar Jeetendra | June 18, 2020 Mumbai 18th June 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) and Roche Products (India) Pvt. Ltd. (Roche Pharma) today announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India. Under this agreement, Cipla will be responsible for …
Cipla launches Cipremi:remdesivir lyophilised powder for injection 100 mg Kumar Jeetendra | June 21, 2020 Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced the launch of remdesivir under its brand name CIPREMI. The U.S. FDA issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc. for emergency use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. It is the only …
Cipla and Boehringer Ingelheim forge partnership to co-market three oral anti-diabetic drugs Kumar Jeetendra | June 29, 2020 Mumbai, June 29, 2020 : Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”) and Boehringer Ingelheim India Pvt. Ltd. (BI) today announced their partnership in India to co-market three new oral anti-diabetics drugs Oboravo® (Empagliflozin), Oboravo Met® (Empagliflozin+Metformin) and Tiptengio® (Empagliflozin+Linagliptin) Empagliflozin is approved for glucose-control in patients with type-2 diabetes; …
Cipla receives final approval for generic version of Shire’s Firazyr® Kumar Jeetendra | July 14, 2020 Mumbai, India; July 14, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA). Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated …
Cipla receives regulatory approval for launch of Ciplenza in India to treat mild to moderate COVID-19 Kumar Jeetendra | July 24, 2020 Mumbai, India; July 24, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of …
Working together with govt organizations to create treatment for COVID-19: Cipla Kumar Jeetendra | August 5, 2020 Medication major Cipla is working together with government agencies to come up with a treatment for COVID-19 while ramping up the production of various life saving essential drugs, according to company’s chairman YK Hamied. Sharing information with business’s shareholders at the drug firm’s annual report for 2019-20, Hamied said the company is at the forefront …
Cipla scales up assembling of remdesivir to fulfill high need Kumar Jeetendra | August 11, 2020 Medicine manufacturer Cipla said on Tuesday it is rising up the production of antiviral drug remdesivir, used in COVID-19 treatment, by manufacturing the drug at its Goa plant. “Presently the requirement is enormous for remdesivir, also we’re scaling up our internal production of Remdesivir,” Kedar Upadhye, global chief financial officer of Cipla, told Moneycontrol. Upadhye …
Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI) Kumar Jeetendra | August 20, 2020 India, Mumbai, August 20th , 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due …
Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis Kumar Jeetendra | October 20, 2020 Mumbai, India; October 20, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib. This launch marks yet …
Cipla Launches ‘CIPtest’ Rapid Antigen Detection Test for COVID-19 Diagnosis Kumar Jeetendra | December 16, 2020 Mumbai, India; December 16, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced its partnership with the Premier Medical Corporation Private Limited for commercialisation of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week. This is Cipla’s second launch in the diagnostics …
